Three Startups Each win CHF 40,000: RatioX, Swiss Medical Union and deepCDR Biologics
21.01.2020
Startups developing transmission for cyclists, a platform to find the right treatment for cancer and deep learning for drug discovery each win 40,000 francs and the next level of entrepreneurial training from Venture Kick.
 |
 |
 RatioX Sàrl founder Simon Faneco
|
|
 Swiss MedicalUnion's CFO Emanuele Pizzatti and Founder Daniil Golubev Founder
|
|
 deepCDR Biologics AG co-founders Derek Mason and Simon Friedensohn
|
|
RatioX Sàrl: continuously variable transmission for bikes
Product design engineer and IMD MBA graduate Simon Faneco founded ratioX to develop a bicycle transmission system that means riders never need to change gear. This user-friendly product simplifies cycling and is low maintenance, making it ideal for commuters and cyclists who value reliable and practical mobility. Faneco now seeks to validate the design with testing after completing a demonstrator prototype, as ratioX targets the ebike market set to reach CHF 3 billion by 2030.
Swiss Medical Union: Finding the right treatment for cancer patients avoiding test on animals
Current in-vivo testing via animal and human studies is expensive and lengthy – predictions to individual patient results are impossible. Especially, Cancer patients are being treated with several different Chemo-Therapies until responding to one treatment. Swiss Medical Union team, Daniil Golubev - CEO & Founder, Marion Argi – CMO and Andrew Alikimovitch, CTO from the University of Geneva (UNIGE) is leveraging an ex-vivo platform to predict individual in vivo results via a micro- bioreactor and simulation software. The goal of this platform is to increase the efficiency and speed of finding the appropriate treatment for the patient without having to try it on an animal or the patient himself, avoiding all the negative consequences that might arise should the drug be the wrong one. Currently they have the prototypes and are about to start the testing session in Germany. the Swiss testing will start within the next couple of months. The Venture Kick funds will be used to get the CE Mark for Bioreactor & Test, a clinical evaluation and an Adaptation of Bioreactor from minimum viable product to full product.
https://medicalunion.swiss/
DeepCDR Biologics AG: deep learning for antibody discovery
Currently, drug-developers searching for new therapeutic antibodies use time-consuming, experimental screening processes that can take years to develop candidates ready for clinical trial. DeepCDR's co-founders Derek Mason, Simon Friedensohn, Sai Reddy, and André Mercanzini, combine gene editing, deep sequencing and deep learning to radically accelerate the therapeutic antibody discovery process. This ETH-spinoff's patented discovery workflow combines drug screening in mammalian cells with deep learning to generate thousands of optimized lead candidates at ten-times the speed of current technology, focusing on the $100 billion monoclonal antibody market.
Product design engineer and IMD MBA graduate Simon Faneco founded ratioX to develop a bicycle transmission system that means riders never need to change gear. This user-friendly product simplifies cycling and is low maintenance, making it ideal for commuters and cyclists who value reliable and practical mobility. Faneco now seeks to validate the design with testing after completing a demonstrator prototype, as ratioX targets the ebike market set to reach CHF 3 billion by 2030.
Swiss Medical Union: Finding the right treatment for cancer patients avoiding test on animals
Current in-vivo testing via animal and human studies is expensive and lengthy – predictions to individual patient results are impossible. Especially, Cancer patients are being treated with several different Chemo-Therapies until responding to one treatment. Swiss Medical Union team, Daniil Golubev - CEO & Founder, Marion Argi – CMO and Andrew Alikimovitch, CTO from the University of Geneva (UNIGE) is leveraging an ex-vivo platform to predict individual in vivo results via a micro- bioreactor and simulation software. The goal of this platform is to increase the efficiency and speed of finding the appropriate treatment for the patient without having to try it on an animal or the patient himself, avoiding all the negative consequences that might arise should the drug be the wrong one. Currently they have the prototypes and are about to start the testing session in Germany. the Swiss testing will start within the next couple of months. The Venture Kick funds will be used to get the CE Mark for Bioreactor & Test, a clinical evaluation and an Adaptation of Bioreactor from minimum viable product to full product.
https://medicalunion.swiss/
DeepCDR Biologics AG: deep learning for antibody discovery
Currently, drug-developers searching for new therapeutic antibodies use time-consuming, experimental screening processes that can take years to develop candidates ready for clinical trial. DeepCDR's co-founders Derek Mason, Simon Friedensohn, Sai Reddy, and André Mercanzini, combine gene editing, deep sequencing and deep learning to radically accelerate the therapeutic antibody discovery process. This ETH-spinoff's patented discovery workflow combines drug screening in mammalian cells with deep learning to generate thousands of optimized lead candidates at ten-times the speed of current technology, focusing on the $100 billion monoclonal antibody market.